Latest clinical evidence of maintenance therapy in ovarian c... : Current Opinion in Obstetrics
and Gynecology Latest clinical evidence of maintenance therapy in ovarian cancer : Current …

Abstract Purpose of Review Advanced epithelial ovarian cancer remains the most lethal
gynaecological cancer. Most patients with advanced disease will relapse within 3 years after …

The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful
survival endpoint (overall, symptom-free, progression-free) while at the same time not …

Approximately 1% of women in the United States will be diagnosed with epithelial ovarian
cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage …

Ovarian tumor is the gynecological cancer associated with the highest mortality. Most
diseases are diagnosed at an advanced stage, which impairs the chances of prolonged …

Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically
approximately 70% of patients with a complete clinical response to surgery and adjuvant …

Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most
patients will ultimately develop recurrent disease. The benefits of detection and early …

These data led American and European Treatment guidelines to include bevacizumab,
olaparib, niraparib, rucaparib, and combination bevacizumab-olaparib as maintenance …

OBJECTIVES: Ovarian cancer (OC) typically is diagnosed at advanced stages, in which the
primary goal of therapy is to prolong progression-free survival (PFS) and overall survival …

The principle of using molecular targeted therapy to prolong the control of ovarian cancer
has been clearly demonstrated. The greatest effect is on prolongation of PFS and, by adding …